Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of differentiated human antibody therapeutics for the treatment of cancer. The Company's product pipeline includes Darzalex (daratumumab), which is in Phase III clinical development for the treatment of multiple myeloma; MOR208, which is in Phase IIa clinical development for the treatment of non-Hodgkin's lymphoma, and MOR202, which is in Phase II clinical development for the treatment of multiple myeloma. The Company has collaborations with pharmaceutical and biotechnology companies and research institutions. Its partners include Janssen Biotech, Inc., Novo Nordisk A/S, Seagen Inc., BioNTech AG, Immatics Biotechnologies GmbH, and Bolt Biotherapeutics, Inc., among others.